Marc P Bonaca, Deepak L Bhatt, Tabassome Simon, Kim Michael Fox, Shamir Mehta, Robert A Harrington, Lawrence A Leiter, Warren H Capell, Claes Held, Anders Himmelmann, Wilhelm Ridderstråle, Jersey Chen, Jane J Lee, Yang Song, Marielle Andersson, Jayne Prats, Mikhail Kosiborod, Darren K McGuire, Ph Gabriel Steg
BACKGROUND: Ticagrelor reduced major adverse cardiovascular events (MACE) and increased bleeding in patients with type 2 diabetes mellitus (T2DM) and coronary artery disease. Limb events including revascularization, acute limb ischemia (ALI), and amputation are major morbidities in patients with T2DM and atherosclerosis. OBJECTIVES: This study sought to determine the effect of ticagrelor on limb events. METHODS: Patients were randomized to ticagrelor or placebo on top of aspirin and followed for a median of 3 years...
April 30, 2024: Journal of the American College of Cardiology